LncRNA MIAT enhances cerebral ischaemia/reperfusion injury in rat model via interacting with EGLN2 and reduces its ubiquitin-mediated degradation

Suping Li¹ | Jing Fu² | Yi Wang³ | Chunmei Hu⁴ | Fei Xu¹

Abstract
Long non-coding RNA (lncRNA) MIAT (myocardial infarction associated transcript) has been characterized as a functional lncRNA modulating cerebral ischaemic/reperfusion (I/R) injury. However, the underlying mechanisms remain poorly understood. This study explored the functional partners of MIAT in primary rat neurons and their regulation on I/R injury. Sprague-Dawley rats were used to construct middle cerebral artery occlusion (MCAO) models. Their cerebral cortical neurons were used for in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) models. Results showed that MIAT interacted with EGLN2 in rat cortical neurons. MIAT overexpression or knockdown did not alter EGLN2 transcription. In contrast, MIAT overexpression increased EGLN2 stability after I/R injury via reducing its ubiquitin-mediated degradation. EGLN2 was a substrate of MDM2, a ubiquitin E3 ligase. MDM2 interacted with the N-terminal of EGLN2 and mediated its K48-linked poly-ubiquitination, thereby facilitating its proteasomal degradation. MIAT knockdown enhanced the interaction and reduced EGLN2 stability. MIAT overexpression reduced oxidative pentose phosphate pathway flux and increased oxidized/reduced glutathione ratio, the effects of which were abrogated by EGLN2 knockdown. In conclusion, MIAT might act as a stabilizer of EGLN2 via reducing MDM2 mediated K48 poly-ubiquitination. MIAT-EGLN2 axis exacerbates I/R injury via altering redox homeostasis in neurons.

KEYWORDS
EGLN2, ischaemic stroke, ischaemic/reperfusion injury, MDM2, MIAT

INTRODUCTION
Ischaemic stroke is the dominant subtype of all strokes and remains a leading cause of death and disability worldwide.¹ Currently, thrombolysis using recombinant human tissue plasminogen activator is still the only clinically effective therapeutic strategy.¹ However, due to the narrow therapeutic window (≤4.5 h since the onset of symptoms), only a small proportion of patients received timely treatment.¹ Besides, reperfusion

¹Department of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China
²Department of Rehabilitation, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China
³Department of Specialty of Geriatric Endocrinology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China
⁴Department of Otolaryngology-Head and Neck Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China

Correspondence
Chunmei Hu, Department of Otolaryngology-Head and Neck Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, 610072, China. Email: qingyikuqima@163.com
Fei Xu, Department of Neurology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, 610072, China. Email: 476627450@qq.com

Funding information
This study was supported by the Key Research Project of Science & Technology Department of Sichuan Province, China (2021YFS0131 and 2020YFS0414)
is associated with complex physiological alterations (such as oxidative stress, neuroinflammation and excitotoxicity), leading to induced neuronal apoptosis and neurovascular injury. Therefore, a clear understanding of the molecular mechanisms of ischaemic/reperfusion (I/R) injury would provide new opportunities for palliative interventions.

Long non-coding RNAs (lncRNAs) are a class of mRNA-like transcripts than 200 nucleotides in length but lacking protein-coding activity. They regulate many fundamental biological processes and pathophysiological events at transcriptional, post-transcriptional and translational levels. MIAT (myocardial infarction associated transcript), also known as RNCR2 (retinal non-coding RNA 2), is a lncRNA that is involved in various diseases, such as myocardial infarction, diabetic complications, ischaemic stroke and cancers. For example, it binds to and stabilizes NF-E2-related factor 2 (Nrf2), thereby exaggerating high glucose induced renal tubular epithelial injury. It enhances inflammation and oxidative stress in sepsis-induced cardiac injury by sponging miR-330-5p and activating the downstream TRAF6/NF-xB signalling. It promotes hypoxia/reoxygenation-induced myocardial cell apoptosis by activating Akt/GSK-3β signalling. Its upregulation is also observed in brain tissues after ischaemic stroke, which promotes neural cell autophagy and apoptosis via reducing ubiquitin-mediated degradation of regulated development and DNA damage responses 1 (NEDD1). Therefore, it might be a critical lncRNA mediating I/R injury.

Egl-9 Family Hypoxia Inducible Factor 2 (EGLN2, also known as PHD1) is a member of the prolyl hydroxylase domain proteins (PHDs), including PHD1-3. It is an oxygen sensor and a critical regulator of the response to hypoxia. In normoxia, PHDs mediate hydroxylation targets proteins for proteasomal degradation. One previous study showed that the PHD1 exerts a critical neuroprotective role in ischaemic stroke. PHD1−/− mice had 71% reduction in infarcted size 24 h after permanent middle cerebral artery occlusion (pMCAO), without vascular changes. Cortical neurons from PHD1−/− mice are less susceptible to I/R injury due to a shifting of glucose oxidation to oxidative pentose phosphate pathway (oxPPP). Therefore, EGLN2 inhibition has been considered as a potential strategy to diminish neuronal damage under the risk of cerebral ischaemia.

In the current study, we investigated the functional partner of MIAT in primary rat neurons and identified a physical interaction between MIAT and EGLN2. MIAT increases EGLN2 stability in cortical neurons after I/R injury and modulates oxidized (GSSG) and reduced (GSH) glutathione ratio.

## Materials and Methods

### 2.1 Prediction of MIAT binding partners

Proteins that might interact with MIAT were predicted using RNAInter (http://www.rna-society.org/main/en/home.html). The protein sequence of rat EGLN2 was obtained from Uniprot (Q6AYU4). The possible binding sites between MIAT (NR_111959.1) and EGLN2 protein sequence were also predicted using the PRIdictor module of RNAInter.

### 2.2 Primary culture of rat cortical neurons

Primary cortical neurons were obtained from newborn Sprague-Dawley rat brain tissue, according to the methods introduced previously. Briefly, the primary cortical neurons were maintained in a culture medium with 97% Neurobasal Medium, 2% B27, 1% penicillin and streptomycin (complete medium). Six days after isolations, the primary neurons were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) treatment. The cells were washed twice and were cultured in glucose-free DMEM. Then, the cells were maintained in a tri-gas incubator containing 94% N₂, 1%O₂ and 5% CO₂ for 2 h at 37°C. Then, the culture medium was replaced by the complete medium, and the cells were further incubated in a normal incubator for 6, 12 or 24 h.

### 2.3 Transfection and infection reagents

MIAT locked nucleic acid (LNA) gaimer antisense oligonucleotides (ASOs) (sequence 5′-AAGATGTAGCATGACTC-3′) and the scramble controls were chemically synthesized by Ribobio (Guangzhou, China).

The following adeno-Associated Viral Vector 5 (AAV5) based AAVs were generated by Hanbio Biotechnology (Shanghai, China), including MIAT (NR_111959.1) overexpression (AAV5-MIAT) (titre 3.1 × 10^{12} GC/ml), AAV5-EGLN2 shRNA (AAV5-shEGLN2) (titre 2.2 × 10^{12} GC/ml), AAV5-vector control (AAV5-vector, 5 × 10^{12} GC/ml) and AAV5-shRNA control (titre 5.5 × 10^{12} GC/ml). The following validated sequence for the shEGLN2 were used: 5′-GCTGCATACCTGTATCTTATT-3′.

The following lentiviral shuttle plasmids for gene overexpression were generated based on pHBLV-CMVIE-ires-ZsGreen, including EGLN2 (NM_001004083.1) overexpression with myc-tag (lg-myc-EGLN2), MDM2 (NM_001108099.1) overexpression with flag-tag (lg-flag-MDM2), ubiquitin with HA tag (lg-Ub-HA) and the mutant constructs with only one lysine residue but all other mutants (K48 and K63), plKO.1-Puro lentiviral shuttle plasmid was used to MDM2 shRNA (lg-shMDM2) for gene knockdown. The following sequences for the shMDM2 were used: #1, 5′-GGGAATGCACCTCGTGCAATG-3′; #2, 5′-GCACCTCGTGCAATGAAATGA-3′. Lentiviruses for infection were produced by co-transfecting the shuttle plasmids and packaging plasmids (psPAX2+pMD2.G) into 293T cells as previously described. Cells were infected with lentivirus at the multiplicity of infection of 15. Proteasome inhibitor MG132 and protein synthesis inhibitor Cycloheximide (CHX, ≥99%) were purchased from Selleck (Shanghai, China).

### 2.4 Middle cerebral artery occlusion (MCAO) model in rats

Male Sprague-Dawley rats were weighted around 220–250 g were purchased from Chengdu Dashuo Biotechnology Co., Ltd (Chengdu, China). All animal experiments were performed under the guidelines evaluated
and approved by the ethics committee of Sichuan Provincial People's Hospital and in accordance with the guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health. Rats were maintained in a specific pathogen free laboratory animal care facility.

Animals were randomly divided into the following groups: sham-operated group (N = 10); MCAO + ASO-NC (N = 25); MCAO + MIAT-ASO (N = 25); MCAO + vector (N = 10); MCAO + MIAT (N = 12); MCAO + MIAT + shNC (N = 12); and MCAO + MIAT + shEGLN2 (N = 12).

GapmeRs control (ASO-NC) and MIAT-ASO (20 mg/kg) were intravenously (i.v.) injected via the tail vein. 48 h later, the rats were subjected to MCAO operation. For the other four groups, rats were anaesthetized and fixed to a stereotaxic apparatus (Stoelting, Kiel, WI, USA) and then were subjected to adenovirus injection. For each group, a total of 10 μl adenoviral solution was injected: vector alone group (5 × 10^9 GC in 10 μl), MIAT group (AAV5-MIAT: 5 × 10^9 GC/10 μl), MIAT + shNC group (AAV5-MIAT: 5 × 10^9 GC/5 μl and AAV5-shNC: 5 × 10^9 GC/5 μl) and MIAT + shEGLN2 group (AAV5-MIAT: 5 × 10^9/μl + AAV5-shEGLN2: 5 × 10^9 GC/5 μl). Adenoviruses were injected into the right cerebral ventricle of rats, using a Hamilton microsyringe at bregma backwards 1 mm, 15 mm lateral and 4 mm dorsoventral. The rate of the injection was 0.5 μl/min. Subsequently, the needle was fixed for 5 min and slowly removed within 2 min. Three days post-injection, rats were subjected to MCAO operation.

MCAO operation was established as described previously.\textsuperscript{14} Briefly, rats were anaesthetized by intraperitoneal (IP) injection of pentobarbital sodium (40 mg/kg). Then, a midline neck incision was performed, and the right common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA) were surgically exposed. The ECA was permanently ligated. A 4–0 monofilament nylon suture with a 0.26 mm diameter rounded tip was aseptically inserted into the right CCA lumen and gently advanced into the ICA for a point 19–20 mm beyond the bifurcation of the CCA. After 90 min of occlusion, reperfusion was conducted by removing the nylon filament, followed by different time intervals of reperfusion (3, 6, 12, 18 and 24 h). The brain tissues obtained from each group were collected for the following experimental procedures.

2.5 | 2,3,5-Triphenyltetrazolium chloride (TTC) staining

The rats were euthanized under anaesthesia 24 h after MCAO. Then, the brains were rapidly removed, cut into 2-mm-thick slices and stained with 2% TTC (Sigma-Aldrich, St. Louis, MO, USA) solution at 37°C for 30 min. The stained slices were photographed, and pale-appearing infarcted areas were digitally analysed to calculate the infarct volume, using ImageJ software (NIH, USA).

2.6 | qRT-PCR analysis

RNA extraction, cDNA synthesis and qRT-PCR were conducted according to the protocol introduced in one previous study.\textsuperscript{15} Gene expression was quantified by calculating fold changes using the formula 2^−ΔΔCT method. GAPDH expression served as an internal control. The primers used were provided in Table S1.

2.7 | RNA pull-down assay

Briefly, MIAT and its antisense RNA were chemically synthesized and were inserted into the sites between KpnI and SacI in pBlue-script II SK+. The sense and antisense MIAT were transcribed in vitro using MAXiscript T7/T3 Transcription Kit (Thermo Fisher Scientific, Carlsbad, CA, USA). Then, the lncRNAs were labelled with biotin using a Biotin RNA Labeling Mix (Roche, Germany) and purified using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Then, cell lysate from primary rat neurons with EGLN2 overexpression was prepared. RNA pull-down assay was performed using a Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific), according to the manufacturer’s instruction. The retrieved protein was eluted from the RNA-protein complex and was subjected to SDS-PAGE. Sense MIAT-specific gel bands were excised and trypsin digested. Then, the peptides were analysed by liquid chromatography tandem mass spectroscopy (LC-MS/MS), following the method introduced previously.\textsuperscript{16}

2.8 | RNA immunoprecipitation (RIP)-qPCR

RIP assays were conducted using the EZ-Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Merck Millipore), according to the manufacturer’s instruction. Briefly, 72 h after AAV-EGLN2 overexpression, primary rat neurons were harvested, washed and lysed using RIPA buffer. Then, whole-cell lysate was incubated with the RIP immunoprecipitation buffer containing protein A/G magnetic beads coated with EGLN2 antibody. Normal rat IgG was used as the control. The precipitated RNA fraction was isolated and subjected to qRT-PCR analysis of MIAT expression.

2.9 | Western blotting

Western blot was performed as described previously.\textsuperscript{15} In brief, total proteins were extracted from cell or tissue samples. Then, protein concentrations were determined using the BCA assay (Pierce, Rockford, IL, USA). Samples containing 30 μg protein were loaded to each lane, subjected to 12% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were incubated consecutively with primary antibodies followed by appropriate HRP-conjugated secondary antibodies. Protein band signals were developed using BeyoECL Star (Chemiluminescence; Beyotime, Wuhan, China) with ChampGel full automatic gel imaging system (Sage Creation Science, Beijing). The primary antibodies and dilutions were provided in Table S1.
2.10 | Immunofluorescent staining

Primary neurons were grown on coverslips, fixed in 4% paraformaldehyde, permeabilized and blocked. Then, the cells were incubated with rabbit anti-EGLN2 (1:50, 12984–1-AP, Proteintech) and mouse anti-MDM2 (1:100, 66511–1-lg, Proteintech) at 4°C overnight. Then, the coverslips were washed thoroughly and incubated with secondary antibodies conjugated to Alexa Fluor 647 or 488. Nuclear was stained by DAPI. Immunofluorescent staining was visualized with a fluorescence microscope (Olympus IX83, Tokyo, Japan).

2.11 | Co-immunoprecipitation (Co-IP)

Co-IP was conducted using Pierce Co-Immunoprecipitation Kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. In brief, primary anti-Flag tag (10 μg) or anti-Myc tag (10 μg) were immobilized to AminoLink Plus coupling resin. Then, primary rat neurons were collected and lysed using IP lysis buffer. The supernatant of cell lysate was collected, precleared using control agarose resin and then was added to the spin column containing the antibody-coupled resin. Then, the spin column was gently wobbled overnight at 4°C. Then, the spin column was centrifuged and washed. The immunoprecipitated proteins were eluted and then were subjected to Western blot analysis.

2.12 | HE, Nissl and Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labelling (TUNEL) assay

HE and Nissl staining were performed to assess morphological changes after I/R injury. Brain tissues of each group were collected, fixed with paraformaldehyde, dehydrated, dipping in wax, embedded and sectioned. Then, sections were stained with HE or cresyl violet (Nissl staining). Apoptotic neurons in the brain were visualized by TUNEL staining. Cross-comparison identified 12 high potential candidate (Figure 1B, 1C, red arrows) were excised, enzymatically digested, and then subjected to LC-MS/MS assay. The candidates identified by LC-MS/MS were cross-compared with the predicted MIAT-interacting proteins by RNAInter (Figure 1C). Cross-comparison identified ENLG2 (48 kD) as a high potential candidate (Figure 1B, 1C, red arrows). It has been characterized as an important player contributing to neuronal damage after ischaemic stroke.

Bioinformatic prediction identified 12 high potential binding sites between MIAT and EGLN2 proteins (Figure 1D). To validate the predicted binding, RNA pull-down assay was conducted using biotin-labelled sense and antisense MIAT by in vitro transcription (Figure 1A) and conducted RNA pull-down assay in the lysates of primary rat cortical neurons (Figure 1B). Then, SDS-PAGE was performed to separate the samples. Sense MIAT-specific bands (Figure 1B, arrows) were excised, enzymatically digested, and then were subjected to LC-MS/MS assay. The candidates identified by LC-MS/MS were cross-compared with the predicted MIAT-interacting proteins by RNAInter (Figure 1C). Cross-comparison identified ENLG2 (48 kD) as a high potential candidate (Figure 1B, 1C, red arrows). It has been characterized as an important player contributing to neuronal damage after ischaemic stroke.

2.13 | Oxygen consumption rate (OCR) quantitation

OCR was measured using a Seahorse XF96 (Agilent Technologies, Santa Clara, CA, USA) with the Cell Mito Stress Test Kit (Cat No. 103015–100, Agilent Technologies), following the manufacturer’s instructions. OCR was normalized to the cell number as determined by CellTiter-Glo analysis at the end of the experiments.

2.14 | Metabolic flux assays

Oxidative pentose phosphate pathway (oxPPP) flux was measured using the isotopic non-stationary gluconate tracer method, as described previously. Oxidized (GSSG) and reduced (GSH) glutathione ratios were measured using LC-MS, as described previously.

2.15 | Statistical analysis

All experiments were repeated three times independently. Quantitative data were reported as means ± standard deviation (SD), based on at least three repeats of three independent tests. Unpaired t test with Welch’s correction was used to compare the difference between two groups. One-way ANOVA with Sidak’s multiple comparisons test was conducted for multiple-group comparison. p < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | MIAT interacts with EGLN2 in rat cortical neurons

To explore the potential functional interactor of MIAT, we generated biotin-labelled sense and antisense MIAT by in vitro transcription (Figure 1A) and conducted RNA pull-down assay in the lysates of primary rat cortical neurons (Figure 1B). Then, SDS-PAGE was performed to separate the samples. Sense MIAT-specific bands (Figure 1B, arrows) were excised, enzymatically digested, and then were subjected to LC-MS/MS assay. The candidates identified by LC-MS/MS were cross-compared with the predicted MIAT-interacting proteins by RNAInter (Figure 1C). Cross-comparison identified ENLG2 (48 kD) as a high potential candidate (Figure 1B, 1C, red arrows). It has been characterized as an important player contributing to neuronal damage after ischaemic stroke.

Bioinformatic prediction identified 12 high potential binding sites between MIAT and EGLN2 proteins (Figure 1D). To validate the predicted binding, RNA pull-down assay was conducted using biotin-labelled sense and antisense MIAT and the lysate of primary rat neurons with EGLN2 overexpression (Figure 1E, 1F). Western blot assay confirmed the presence of EGLN2 in the samples pulled down by sense MIAT, but not in the samples pulled down by antisense MIAT (Figure 1G). Then, RIP-qPCR was conducted to check the enrichment of MIAT in the samples precipitated by anti-EGLN2 or IgG control (Figure 1H, 1I). Results indicated that MIAT was significantly enriched in the anti-EGLN2 group (Figure 1I).

3.2 | MIAT increases EGLN2 stability in cortical neurons after I/R injury

In rat model of MCAO, EGLN2 protein expression was significantly elevated as early as 3 h after reperfusion and was significantly higher at all time points (3, 6, 12, 18 and 24) when compared with the sham-operated control group (Figure 2A, 2B, left panel). At the same time, MIAT expression was also significantly upregulated after I/R injury (Figure 2C, left panel). MIAT knockdown significantly
attenuated I/R induced EGLN2 upregulation at the protein level (Figure 2A, 2B, right panel), but not the mRNA level (Figure 2D).

OGD/R treatment in vitro induced EGLN2 upregulation, the trend of which was impaired by MIAT knockdown (Figure 2E). However, MG132 treatment resulted in EGLN2 accumulation and also cancelled the effect of MIAT knockdown (Figure 2E), suggesting that MIAT might influence the proteasomal degradation of EGLN2. Cycloheximide chase analysis showed that MIAT knockdown facilitated EGLN2 degradation (Figure 2F and 2H), while MIAT overexpression slowed the degradation process (Figure 2G and 2I).

3.3 | MDM2 interacts with EGLN2 and promotes its degradation

To explore the underlying mechanisms of EGLN2 degradation, we predicted E3 ubiquitin ligases interacting with EGLN2 using UbiBrowser\(^\text{25}\) (http://ubibrowser.ncpsb.org/). Only the candidates with high confidence interaction score (>0.7) were identified, including murine double minute 2 (MDM2), synovial apoptosis inhibitor 1 (SYVN1) and STIP1 Homology And U-Box Containing Protein 1 (STUB1) (Figure 3A). MDM2 is an E3 ligase involved in cerebral I/R injury (20), with the highest confidence score, IF staining confirmed the co-localization of EGLN2 and MDM2 in primary rat neurons (Figure 3B). Then, co-IP assay was conducted in primary neurons with enforced overexpression of flag-MDM2 or myc-EGLN2 (Figure 3C). Results showed that flag-MDM2 could be immunoprecipitated by anti-myc, while myc-EGLN2 could be immunoprecipitated by anti-flag (Figure 3C). MDM2 overexpression or knockdown did not alter EGLN2 transcription (Figure 3D) but negatively modulated EGLN2 expression at the protein level (Figure 3E, 3F). MDM2 overexpression decreased EGLN2 stability, while its downregulation increased EGLN2 stability (Figure 3G, 3I).
3.4 MIAT reduces MDM2 mediated K48-linked poly-ubiquitination of EGLN2

MDM2 overexpression significantly increased poly-ubiquitination of EGLN2, the effect of which was weakened by MIAT overexpression (Figure 4A). To identify the specific type of ubiquitin linkage catalysed by MDM2 on EGLN2, two Ub mutants with only K48 or K63 residue, but all other lysine residues replaced with arginine were generated. Primary rat neurons were coinfected with myc-EGLN2, flag-MDM2 and wild-type or mutant HA-Ub constructs. Co-IP assay showed that MDM2 enhanced the K48 poly-ubiquitination of EGLN2 (Figure 4B). MIAT knockdown also increased EGLN2 K48 poly-ubiquitination after OGD/R treatment (Figure 4C). Bioinformatic prediction in UbiBrowser indicated that MDM2 might interact with the N terminal of EGLN2 (Figure S1). Therefore, truncated EGLN2 constructs with an N-terminal Myc tag (Figure 4D). When the EGLN2 constructs were co-expressed with flag-tagged MDM2 in primary rat neurons, only the constructs containing the N terminal (FL and N88) could interact with MDM2 (Figure 4E). OGD/R treatment increased the binding of N88 with MDM2 (Figure 4F). MIAT knockdown weakened the binding (Figure 4F).
3.5 | MIAT-EGLN2 axis modulates I/R induced ischaemic brain damage

In the rat cerebral ischaemic model, MIAT overexpression enhanced I/R injury, in terms of infarct volume (Figure 5A, 5B), neuron damage (Figure 5C, 5D) and apoptosis (Figure 5E). However, EGLN2 knockdown abrogated and reversed the detrimental effect of MIAT overexpression (Figure 5A–5E). Western blot analysis with an anti-Flag or anti-Myc antibody confirmed that MIAT overexpression enhanced I/R injury-induced Bax and cleaved caspase-3 expression but suppressed the expression of Bcl-2 (Figure 5F, 5G). In comparison, EGLN2 knockdown significantly alleviated these alterations (Figure 5F, 5G).

3.6 | MIAT-EGLN2 axis modulates oxidized (GSSG) and reduced (GSH) glutathione ratio in rat neurons

One recent study showed that in EGLN2−/− neurons, glycolysis, glucose consumption and glucose oxidation were significantly downregulated. In comparison, the activity of the oxPPP was enhanced. In the oxPPP pathway, NADPH is generated as a reducing equivalent by glutathione reductase to regenerate GSH, which serves as a critical antioxidant in neurons. Thus, we further investigated whether the MIAT-EGLN2 axis modulates carbon metabolism in rat neurons. Seahorse XF96 analyzer was utilized to measure the changes in mitochondrial respiration. In primary rat neurons, MIAT knockdown or overexpression did not alter mitochondrial respiration (Figure 6A, 6B). In comparison, MIAT knockdown increased oxPPP flux, while MIAT overexpression decreased the flux (Figure 6C, 6D). EGLN2 knockdown reversed MIAT overexpression induced alteration (Figure 6D). Quantitation of oxidized (GSSG) and reduced (GSH) glutathione 6 h after OGD/R indicated that MIAT overexpression increased the ratio of oxidized glutathione, EGLN2 knockdown drastically reduced the ratio (Figure 6E). Based on these findings, we infer that I/R injury induces MIAT upregulation in rat neurons (Figure 6F). MIAT enhances EGLN2 stability via reducing MDM2 mediated ubiquitin-proteasomal degradation (Figure 6F). EGLN2 can reduce oxPPP flux and enhance reactive oxygen species (ROS) generation, leading to neuronal death (Figure 6F).
As a lncRNA involved in I/R injury in both cardiac and cerebral tissues, MIAT might participate in complex regulatory networks. It acts as a sponge for miR-1a in cardiomyocytes and exaggerates acute myocardial infarction via elevating the expression of early growth response gene-2 (EGR2).\(^{21}\) Besides, it promotes p65 nuclear translocation and activates NF-kappaB signalling, resulting in elevated expression of cleaved-caspase-3 and Bax and downregulation of Bcl-2 in cardiomyocytes after I/R injury.\(^{22}\) In cerebral microvascular endothelial cells, it sponges miR-204 and increases the expression of high mobility group box-1 protein (HMGB1), leading to enhanced cell apoptosis.\(^{23}\) One recent study noticed that in rat cortical neurons, MIAT enhances cell autophagy and apoptosis by interacting with Regulated in development and DNA damage responses 1 (REDD1) and reducing its ubiquitination mediated degradation.\(^{8}\) This finding suggests that MIAT might serve as a protein stabilizer in cortical neurons.

I/R generally increases intraneuronal levels of ubiquitinated proteins, since ischaemia-derived free radicals can suppress the activities of deubiquitinases.\(^{24,25}\) Deubiquitinase inhibition has been considered an endogenous protective mechanism to reduce neuronal proteins from oxidative damage.\(^{24}\) However, this opinion is controversial since increased expression and activity of several ubiquitin ligases and associated proteins present neuroprotective effects after cerebral ischaemia, such as STUB1, NEDD4, ITCH and NDFIP1.\(^{25}\) STUB1 overexpression exerts neuroprotective functions in neurological diseases via modulating the degradation
of some chaperone-bound proteins. NDFIP1 binds to PTEN and enhances its ubiquitination mediated by NEDD4 and nuclear import, thereby promoting neuronal survival following cerebral ischaemia. Therefore, it is necessary to consider the specific functions of ubiquitin ligases in stress regulation and neuronal degeneration.

Figure 5 MIAT-EGLN2 axis modulates I/R induced ischaemic brain damage. (A)–(B). Representative photographs (A) and quantitation of infarct area (B) of coronal brain sections stained with TTC, 24 h after I/R injury (n = 6). The white-coloured areas represent the infarct regions in these sections. The rats received stereotactical injection of vector alone (5 × 10⁹ GC in 10 µl), AAV5-MIAT (5 × 10⁹ GC/10 µl), AAV5-MIAT (5 × 10⁹ GC/5 µl) + AAV5-shNC (5 × 10⁹ GC/5 µl) or AAV5-MIAT (5 × 10⁹ GC/5 µl) + AAV-shEGLN2 (5 × 10⁹ GC/5 µl). (C)–(E) HE (C), Nissl (D) and TUNEL (E) staining of neuron damage and apoptosis in each group 24 h after I/R injury. Scale bar indicates 100 µm. (F)–(G) Representative images (F) and quantitation (G) of Western blot analysis of Bax, cleaved caspase-3 (c-caspase-3) and Bcl-2 expression in each group 24 h after I/R injury (n = 3).
The current study found that in rat cortical neurons, MIAT interacted with EGLN2. Enforced MIAT overexpression or knockdown did not alter EGLN2 mRNA expression. In comparison, MIAT increased its stability after I/R injury via reducing its ubiquitin-mediated degradation. MDM2 is an E3 ligase significantly elevated after transient MCAO and serves as a neuroprotective protein by promoting p53 degradation and preventing p53-mediated neuronal apoptotic death. MDM2 knockdown triggers p53 accumulation and increases neuronal susceptibility to OGD/R-induced apoptosis. Similar protect effects of MDM2 were confirmed in primary cultured spinal cord neurons against OGD/R injury. In this study, we identified EGLN2 as a novel substrate of MDM2. MDM2 interacted with the N-terminal of EGLN2. It mediated the K48-linked poly-ubiquitination of EGLN2, thereby facilitating its proteasomal degradation. The presence of MIAT reduced the interaction between MDM2 and EGLN2 and increased EGLN2 stability. By performing in vivo MCAO model in rats, we showed that MIAT overexpression enhanced infarct volume and induced a higher ratio of neuronal apoptosis. EGLN2 knockdown significantly reversed the injury. These findings suggest that EGLN2 is an important downstream effector of MIAT in I/R injury.

One previous study reported that EGLN2−/− mice had significantly smaller infarct area 24 h after 2 h MCAO, compared to the wild-type counterparts, suggesting that EGLN2 exerts critical regulatory effects in I/R injury. However, although EGLN2 is one of the master regulators of the response to hypoxia, it is the hydroxylation activity of EGLN2 mediates its neuroprotective effect. Knocking down of HIF-1α, HIF-2α or HIF-1b could not abolish the protective effect of PHD1 deficiency against oxygen-nutrient deprivation.

During the phase of reperfusion, oxidative stress exacerbates ROS production. The free radicals are highly reactive to a series of molecular targets, including nucleic acids, proteins and unsaturated lipids in cell membranes, generating oxidation-derived products. Some endogenous mechanisms are utilized to balance ROS production, including glutathione, coenzyme Q and some other enzymes (superoxide dismutase, glutathione reductase, glutathione-S-transferase and glutathione peroxidase). However, when ROS production overwhelms the handing capacity of the antioxidants, cellular damage occurs. EGLN2 acts as an important regulator of neuronal energy metabolism. Glucose oxidation is the major energy source of neurons. EGLN2 knockout does not alter oxygen consumption in neurons but increases oxPPP activity at the expense of glycolysis. This metabolic alteration enables neurons better against ischaemia via a greater capacity to generate NADPH to scavenge oxygen radicals. In this study, we found that MIAT reduced oxPPP flux and increased oxidized/reduced glutathione ratio via stabilizing EGLN2.

Bioinformatic analysis in this study also observed that SYVN1 and STUB1 are potential E3 ligase interacting with EGLN2. SYVN1 mediates the ubiquitination and degradation of glutathione peroxidase 5 (GPX5), increasing the generation of ROS and apoptosis of cardiomyocytes. Besides, SYVN1 can enhance I/R induced renal epithelial injury by mediating NRF2 ubiquitylation and degradation. Furthermore, SYVN1 participates in ER-associated degradation of unfolded/misfolded proteins, which is linked to brain ischaemia.

![Figure 6](https://example.com/figure6.png)
Therefore, it is meaningful to explore their potential regulative effect on EGLN2 stability in the future.

In summary, this study identified MIAT as a novel stabilizer of EGLN2, via reducing MDM2 mediated K48 poly-ubiquitination. MIAT-EGLN2 axis exacerbates I/R injury via altering redox homeostasis in neurons. Future studies are required to explore the therapeutic potential of targeting the MIAT-EGLN2 axis to inhibit neuronal apoptotic cell death after acute ischaemic stroke.

CONFLICT OF INTEREST The authors have on conflict of interest.

AUTHOR CONTRIBUTIONS F. Xu conceived this research; S.-P. Li, J. Fu, C.-M. Hu and Y. Wang collected, analysed and disposed data; S.-P. Li, J. Fu, Y. Wang and F. Xu analysed the tables and assembled the figure; S.-P. Li and F. Xu contributed to all aspects of this study and revised the manuscript for publication.

DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Powers WJ, RabineAb AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.

2. Tobin MK, Bonds JA, Minshall RD, Pelligrino DA, Testai FD, Lazarov O. Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here. J Cereb Blood Flow Metab. 2014;34(10):1573-1584.

3. Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: From disease code to drug role. Acta Pharm Sin B. 2021;11(2):340-354.

4. Sun C, Huang L, Li Z, et al. Long non-coding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci. 2018;25(1):23.

5. Zhou L, Xu DY, Sha WG, Shen L, Lu GY, Yin X. Long non-coding MIAT mediates high glucose-induced renal tubular epithelial injury. Biochem Biophys Res Commun. 2015;464(4):726-732.

6. Xing PC, An P, Hu GY, Wang DL, Zhou MJ. LncRNA MIAT promotes inflammation and oxidative stress in sepsis-induced cardiac injury by targeting miR-330-5p/TRA6/F/NF-kappaB Axis. Biochim Genet. 2020;58(5):783-800.

7. Cong L, Su Y, Wei D, et al. Catechin relieves hypoxia/reoxygenation-induced myocardial cell apoptosis via down-regulating IncRNA MIAT. J Cell Mol Med. 2020;24(3):2356-2368.

8. Guo X, Wang Y, Zheng D, Cheng X, Sun Y. LncRNA-MIAT promotes neural cell autophagy and apoptosis in ischemic stroke by up-regulating REDD1. Brain Res. 2021;1763:147436.

9. Kennel KB, Burmeister J, Schneider M, Taylor CT. The PHD1 oxygen sensor in health and disease. J Physiol. 2018;596(17):3899-3913.

10. Quaegebeur A, Segura I, Schmieder R, et al. Deletion or inhibition of the oxygen sensor PHD1 protects against ischemic stroke by reprogramming of neuronal metabolism. Cell Metab. 2016;23(2):280-291.

11. Lin Y, Liu T, Cui T, et al. RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res. 2020;48(D1):D189-D197.

12. Facci L, Skaper SD. Culture of rodent cortical, hippocampal, and striatal neurons. Methods Mol Biol. 2018;1727:39-47.

13. Xu H, Qin W, Hu X, et al. Lentivirus-mediated overexpression of OTULIN ameliorates microglia activation and neuroinflammation by depressing the activation of the NF-kappaB signaling pathway in cerebral ischemia/reperfusion rats. J Neuroinflammation. 2018;15(1):38.

14. Belayev L, Alonso OF, Bustro R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 1996;27(9):1616-1622. discussion 23.

15. Chelluboina B, Warhekar A, Dillard M, et al. Post-transcriptional activation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage. Sci Rep. 2015;5:9504.

16. Wang C, Li Y, Yan S, et al. Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. Nat Commun. 2020;11(1):3162.

17. Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene. 2016;35(22):2913-2922.

18. Carroll D, Howard D, Zhu H, et al. Simultaneous quantitation of oxidized and reduced glutathione via LC-MS/MS: An insight into the redox state of hematopoietic stem cells. Free Radic Biol Med. 2016;97:85-94.

19. Li Y, Xie P, Lu L, et al. An integrated bioinformatics platform for investigating the human E3 ubiquitin-ligase-substrate interaction network. Nat Commun. 2017;8(1):347.

20. Deliavinti D, Wilkinson-Berka JL. Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina. J Neuroinflammation. 2015;12:136.

21. Cao X, Ma Q, Wang B, et al. Silencing long non-coding RNA MIAT ameliorates myocardial dysfunction induced by myocardial infarction via MIAT/miR-10a-5p/EGR2 axis. Aging. 2021;13.

22. Chen L, Zhang D, Yu L, Dong H. Targeting MIAT induces apoptosis of cardiomyocytes after ischemia/reperfusion injury. Bioengineered. 2019;10(1):121-132.

23. Deng W, Fan C, Shen R, Wu Y, Du R, Teng J. Long noncoding MIAT acting as a ceRNA to sponge microRNA-204-5p to participate in cerebral microvascular endothelial cell injury after cerebral ischemia through regulating HMG1B. J Cell Physiol. 2020;235(5):4571-4586.

24. Kahles T, Poon C, Qian L, et al. Elevated post-ischemic ubiquitination results from suppression of deubiquitination activity and not proteasome inhibition. Cell Mol Life Sci. 2021;78(5):2169-2183.

25. Hochrainer K. Protein modifications with ubiquitin as re-target for neurological diseases. Cell Death Dis. 2020;11(9):727.

26. Howitt J, Lackovic J, Low LH, et al. Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J Cell Biol. 2012;196(1):29-36.

27. Tu Y, Hou ST, Huang Z, Robertson GS, MacManus JP. Increased Mdm2 expression in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1998;18(6):658-669.

28. Vecino R, Burguete MC, Jover-MenguEL T, et al. The MDM2-p53 pathway is involved in preconditioning-induced neuronal tolerance to ischemia. Sci Rep. 2018;8(1):1610.

29. Rodriguez C, Ramos-Araque ME, Dominguez-Martinez M, et al. Single-nucleotide polymorphism 309T>G in the MDM2 promoter determines functional outcome after stroke. Stroke. 2018;49(10):2437-2444.

30. Li J, Chen G, Gao X, et al. p53 participates in the protective effects of ischemic post-conditioning against OGD-reperfusion injury in primary cultured spinal cord neurons. Neurosci Lett. 2017;638:129-134.
32. Wong BW, Kuchnio A, Bruning U, Carmeliet P. Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. Trends Biochem Sci. 2013;38(1):3-11.
33. Orellana-Urzua S, Rojas I, Libano L, Rodrigo R. Pathophysiology of ischemic stroke: role of oxidative stress. Curr Pharm Des. 2020;26(34):4246-4260.
34. Zhang J, Jiang S, Lu C, et al. SYVN1/GPX5 axis affects ischemia/reperfusion induced apoptosis of AC16 cells by regulating ROS generation. Am J Transl Res. 2021;13(5):4055-4067.
35. Zhang J, Zhang J, Ni H, et al. Downregulation of XBP1 protects kidney against ischemia-reperfusion injury via suppressing HRD1-mediated NRF2 ubiquitylation. Cell Death Discov. 2021;7(1):44.
36. Yang W, Paschen W. Unfolded protein response in brain ischemia: A timely update. J Cereb Blood Flow Metab. 2016;36(12):2044-2050.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Li S, Fu J, Wang Y, Hu C, Xu F. LncRNA MIAT enhances cerebral ischaemia/reperfusion injury in rat model via interacting with EGLN2 and reduces its ubiquitin-mediated degradation. J Cell Mol Med. 2021;25:10140-10151. https://doi.org/10.1111/jcmm.16950